详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Meclizine Prevents Ovariectomy-Induced Bone Loss and Inhibits Osteoclastogenesis Partially by Upregulating PXR (vol 8, 693, 2017)

322| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Dept Orthoped,Wuhan,Hubei,Peoples R China; [2]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Dept Otolaryngol Head & Neck Surg,Wuhan,Hubei,Peoples R China[Guo,Jiachao; [3]Li, Weijin; [4]Jing, Xingzhi; [5]Huang, Junming; [6]Zhang, Jiaming; [7]Xiang, Wei; [8]Ren, Ranyue; [9]Lv, Zhengtao; [10]Xiao, Jun; [11]Guo,Fengjing] Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Dept Orthoped,Wuhan,Hubei,Peoples R China [12]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Dept Otolaryngol Head & Neck Surg,Wuhan,Hubei,Peoples R China

出处：

DOI：

ISSN：

关键词： meclizine PXR osteoclast RANKL osteoporosis

摘要：

[This corrects the article on p. 693 in vol. 8, PMID: 29046637.].

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 2 区医学

小类 | 2 区药学

最新[2025]版：

大类 | 3 区医学

小类 | 3 区药学

JCR分区：

出版当年[2016]版：

Q1 PHARMACOLOGY & PHARMACY

最新[2023]版：

Q1 PHARMACOLOGY & PHARMACY

影响因子： 4.4 最新[2023版] 5 最新五年平均 4.4 出版当年[2016版] 4.275 出版当年五年平均 4.418 出版前一年[2015版] 3.831 出版后一年[2017版]

第一作者：

第一作者单位： [1]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Dept Orthoped,Wuhan,Hubei,Peoples R China;

通讯作者：

通讯机构： [1]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Dept Orthoped,Wuhan,Hubei,Peoples R China;

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Meclizine Prevents Ovariectomy-Induced Bone Loss and Inhibits Osteoclastogenesis Partially by Upregulating PXR (vol 8, 693, 2017) [2]Meclizine Prevents Ovariectomy-Induced Bone Loss and Inhibits Osteoclastogenesis Partially by Upregulating PXR [3]Probucol suppresses osteoclastogenesis via activating Nrf2 signaling and ameliorates ovariectomy-induced bone loss [4]Bone-Targeted Biomimetic Nanogels Re-Establish Osteoblast/Osteoclast Balance to Treat Postmenopausal Osteoporosis [5]Inhibition of MAT2A suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss [6]Isofraxidin Inhibits Receptor Activator of Nuclear Factor-kappa B Ligand-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages Isolated from Sprague-Dawley Rats by Regulating NF-kappa B/NFATc1 and Akt/NFATc1 Signaling Pathways [7]Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR [8]Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR (vol 9, 1016, 2018) [9]A potential therapeutic target for regulating osteoporosis via suppression of osteoclast differentiation [10]Corrigendum: Meclizine Prevents Ovariectomy-Induced Bone Loss and Inhibits Osteoclastogenesis Partially by Upregulating PXR.